List view / Grid view
22 November 2013 | By AstraZeneca
Xigduo™ combines dapagliflozin (tradename Forxiga®), a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride in a twice daily tablet...
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
21 November 2013 | By GlaxoSmithKline
“We welcome the CHMP’s positive opinion on dolutegravir – it puts us a step closer to offering this new treatment option to people across Europe who are living with HIV...”
20 November 2013 | By Zealand Pharma
Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide...
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
20 November 2013 | By Daiichi Sankyo Europe
Once-daily edoxaban, evaluated in two treatment arms achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism...
19 November 2013 | By Boehringer Ingelheim
Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention...
19 November 2013 | By AstraZeneca
AstraZeneca announced that it has selected architects Herzog & de Meuron to design its new centre...
19 November 2013 | By AstraZeneca
The NDA filing was based on comprehensive data from the core Phase III KODIAC programme...
18 November 2013 | By Sanofi
Sanofi announced the decision to halt all clinical trials and cancel plans for regulatory filings with its investigational JAK2 inhibitor...
18 November 2013 | By AbbVie
AbbVie's multinational HCV program is the largest all-oral, interferon-free clinical program in GT1 patients being conducted to date...
BMG LABTECH, Inc. - the Microplate Reader Company - and InvivoSciences, Inc. - a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery - announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies.…
18 November 2013 | By Merck
Marketing authorization application also filed with the European Medicines Agency...
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
